Symposium 29：Application of Tuberculosis Treatment in Lung Cancer
| Time (GMT+8) |
Topic | Speaker | Country / Region |
|---|---|---|---|
| 08:30-09:00 | Epidemiology of Tuberculosis and Lung Cancer | Dr. Chia-Hsiang Li | Taiwan |
| 09:00-09:30 | Treatment strategy of NSCLC in patients with active tuberculosis | Dr. Chih-Hsi Kuo | Taiwan |
| 09:30-10:00 | Is antimicrobial drugs also response against lung cancer in lung cancer patient with Mycobacterium tuberculosis coinfections | Dr. Yung-Hung Luo | Taiwan |
Epidemiology of Tuberculosis and Lung Cancer
Abstract:
According to research findings, tuberculosis is a risk factor for lung cancer. Numerous studies have been conducted worldwide on this topic. Multiple pathologists and clinicians have confirmed the association between tuberculosis and lung cancer or bronchogenic carcinoma. Lung cancer is one of the leading causes of cancer-related deaths globally, while tuberculosis is a common past illness. The risk of developing lung cancer slightly increases following a tuberculosis episode. Tuberculosis is significantly associated with adenocarcinoma but not with squamous cell or small cell lung cancer. Tuberculosis may increase the risk of lung cancer through intense and prolonged inflammation in the lungs. Especially in Asia, there is strong epidemiological evidence suggesting a link between tuberculosis and the development of lung cancer, particularly non-small cell lung cancer.
Dr. Chia-Hsiang Li
Taiwan
Treatment strategy of NSCLC in patients with active tuberculosis
Abstract:
In this presentation, we will review a number of evidence from epidemiological case- control, cohort and meta- analysis studies of increased lung cancer (LC) risk in pre- existing TB cases. We will also highlight the association and ability of Mycobacterium tuberculosis (Mtb) to induce the oncogenesis of lung malignancy. In experimental animal model study, exposure to aerosol- containing Mtb sprays in mice produce malignant transformation of cells that result in squamous cell carcinoma. We also review the effects of anti-cancer and anti-tuberculosis treatments in lung cancer patients with active lung TB. Finally, the modern therapeutic algorithm of advanced lung cancer will be discussed and multiple treatment strategies which may link to the suppression of TB-associated pro-tumor effect will be highlighted.
Dr. Chih-Hsi Kuo
Taiwan
Is antimicrobial drugs also response against lung cancer in lung cancer patient with Mycobacterium tuberculosis coinfections
Abstract:
Lung cancer and tuberculosis (TB) are significant global public health challenges. The interrelation between lung cancer and TB has been a focus of research for many years, with a growing body of evidence indicating that TB is linked to an elevated risk and higher mortality rates in lung cancer, and vice versa, establishing a complex interdependence where each condition serves as a risk factor for the other. The management of tuberculosis in patients with lung cancer, particularly in those with advanced non-small cell lung cancer undergoing concurrent anti-tuberculosis and anti-cancer therapies, remains a subject of ongoing investigation. It has been reported that anti-cancer chemotherapy does not hinder effective tuberculosis treatment, even in cancer patients with active TB, underscoring the feasibility and safety of concurrently administering both anti-cancer and anti-tuberculosis treatments across various cancer types. Additional evidence also indicates that both treatments can be safely and effectively implemented in lung cancer patients who also have tuberculosis, and vigilance is necessary for the risk of tuberculosis among lung cancer patients in countries with a high prevalence of tuberculosis. The specific impact of antimicrobial drugs on lung cancer in patients coinfected with Mycobacterium tuberculosis remains an open question. This review consolidates current and emerging clinical study data on treating patients with concurrent lung cancer and TB. Such insights are vital for guiding clinical decision-making for managing patients with this dual diagnosis, aiming to optimize outcomes in this complex patient population.
Dr. Yung-Hung Luo
Taiwan
Prof. Yuh-Min Chen
Taiwan
Current Positions： Head, Department of Chest Medicine, Taipei Veterans General Hospital, Taiwan; President, Taiwan Society of Pulmonary and Critical Care Medicine; and Professor, School of Medicine, National Yang Ming Chiao Tung University
Education： PhD, Institute of Clinical Medicine, National Yang-Ming University
Visiting Scientist, National Cancer Institute of National Institutes of Health, United States
E-mail： ymchen@vghtpe.gov.tw
Dr. Chin-Chou Wang
Taiwan
Education and Training
1. Doctor of Philosophy (PhD), Department of Public health, Kaohsiung Medical University, Taiwan (2016.06)
2. Master of Public Health (MPH), School of Public Health and Tropical Medicine, Tulane University, USA (1993.12)
3. Doctor of Medicine (MD), School of Medicine, China Medical University, Taiwan (1990.06)
Academic Appointment (include Teaching Experience):
1. Professor, School of Medicine, College of Medicine, National Sun Yat-sen University, Taiwan. (2023.02 ~)
2. Professor, Department of Respiratory Care, Chang Gung University of Science and Technology, Taiwan. (2022.02 ~)
Dr. Te-Chun Hsia
Taiwan
During his tenure as an attending physician, Dr. Hsia obtained a Master’s and Ph.D. degree in Medicine from China Medical University. Throughout his service at China Medical University and hospital, he held administrative positions such as Director of the Department of Respiratory Therapy, Coordinator of the Lung Cancer Team and Director of the Respiratory Intensive Care Unit. Currently, he is a professor at China Medical University and serves as the Director of the Intensive Care Medicine Center and Deputy Head of the Department of Internal Medicine at China Medical University Hospital.
Dr. Hsia’s research interests primarily focus on global clinical trials of new drugs for lung cancer. In the field of basic medical research, he emphasizes the study of cell signaling pathways in cancer and genetic polymorphisms in respiratory diseases.
